BACKGROUND: Autoantibodies to cardiac troponins (cTnAAbs) can interfere with the measurement of cardiac troponin I (cTnI) by immunoassays for the diagnosis of myocardial infarction. Therefore, we determined the cTnI binding sites and IgG subclasses of circulating cTnAAbs.
epitopes in cTnI assays. To circumvent the negative interference of the highly heterogeneous cTnAAbs, use of 3 or more unconventionally selected epitopes should be considered.
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Ternary troponin complex, consisting of subunits I, T, and C, is part of the myofibril contractile apparatus in striated muscle cells. Because 2 of these intracellular proteins, troponin I and T, exist as different isoforms in skeletal and cardiac muscle, the measurement of cardiac-specific isoforms (cardiac troponin) in blood serves as the most sensitive means to prove a recent or persistent myocardial injury. This has made cardiac troponins the recommended biomarkers for the diagnosis of acute coronary syndrome (ACS) 3 (1 ). Cardiac troponin-specific autoantibodies (cTnAAbs), however, can interfere with the detection of these clinically important biomarkers by cTnI assays designed according to the IFCC-recommended midfragment approach used in clinical practice (2) (3) (4) . cTnAAbs have been found in a high proportion (5%-20%) of individuals with or without cardiac diseases (5) (6) (7) (8) (9) (10) , and cardiac troponin-specific autoimmune response leading to autoantibody formation can be triggered by any release of cardiac proteins following myocardial injury, for example, after inflammation, ischemia, or cardiotoxic treatments. Nevertheless, the mechanisms for their appearance and maintenance are poorly understood.
Besides being able to interfere with cardiac troponin detection by immunoassays, cTnAAbs may have clinical significance. Recent studies using a mouse model have associated circulating cTnI-specific cTnAAbs with inflammation of the heart muscle and the emergence of symptoms indicative of cardiac disease. These studies have shown that the administration of cTnI-specific monoclonal antibodies (MAbs) induces autoimmune dilated cardiomyopathy in wildtype mice (11 ) and that provocation of an autoimmune response to cTnI, but not cTnT, leads to increased myocardial inflammation and cardiac dysfunction (12, 13 ) . Moreover, the relatively mild cardiac damage and cTnI release in the acute phase of experimental coxsackievirus B3-induced myocarditis gives rise to cTnAAb formation (14 ) .
The possible clinical consequences of circulating cTnAAbs have also been studied in humans. A recent study (10 ) demonstrated that the presence of cTnAAbs may lead to a higher and longer cTnI release in ACS patients. Another study on ACS patients (15 ) indicated that cTnI-specific cTnAAbs may have a negative impact on the recovery of left ventricular function. Nevertheless, some groups have reported that the outcome of cTnAAb-positive patients was not inferior or was even better than that of cTnAAb-negative patients with ischemic cardiomyopathy, dilated cardiomyopathy, heart failure, and/or ACS (6, 16 -19 ) .
The role of cTnAAbs in the etiology of cardiac diseases and the reason for their occurrence even in apparently healthy individuals is not known. Actually, cardiac troponin-specific autoimmunity seems to appear only in certain individuals, and the vast majority of cardiac patients do not develop it (18, 19 ) . In addition, the possible usefulness of cTnAAbs as diagnostic and/or prognostic biomarkers is unclear in the absence of adequately sized studies with long-term follow-up. Because of lack of detailed data on the molecular characteristics of human cTnAAbs, our purpose in this study was to explore more precisely the location of cTnI binding sites and the IgG subclass distribution of cTnAAbs.
Materials and Methods

REAGENTS
All MAbs except 8I7 (International Point of Care, www.ipocdx.com) were kindly provided by HyTest (www.hytest.fi). A summary of MAbs used and their antigens is presented in Table 1 . This information was obtained from the manufacturers' package inserts. We purchased streptavidin (SA)-coated microtiter plates from Kaivogen Oy (www.kaivogen.com) and human cardiac troponin complex (ITC) from HyTest. ITC was diluted into Tris-buffered saline with azide (TSA) (50 mmol/L Tris-HCl, pH 7.75, 150 mmol/L NaCl, 0.5 g/L NaN 3 ) containing 75 g/L bovine serum albumin (BSA) (Millipore/Intergen, www.millipore.com), and the stocks were stored at Ϫ20°C until use.
LABELING OF ANTIBODIES WITH BIOTIN AND LANTHANIDE
CHELATE
Antibodies were labeled with biotin or intrinsically fluorescent europium chelate as described previously (5 Binding sites or epitopes are also given if they were specified by the manufacturer. aa, amino acids. a Cross-reaction with skeletal TnI Ͼ50%.
IMMUNOASSAYS FOR MEASURING THE ANALYTICAL RECOVERY OF ITC COMPLEX
We determined the binding sites of cTnAAbs on the cTnI molecule by comparing the analytical recoveries of ITC in cTnAAb-positive samples to the recoveries in cTnAAb-negative samples. We measured the fluorescence signal from each unspiked and ITC-spiked serum sample with sandwich-type immunoassays using various cTnI-specific MAbs for capture and the same troponin C-specific MAb as a tracer. First, 300 ng biotinylated capture was immobilized to SA-coated microtiter wells in 25 L Kaivogen buffer solution with approximately 1-h incubation at ambient room temperature. Meanwhile, ITC was added into serum aliquots to a final concentration of 30 g/L cTnI and incubated for 1 h at 4°C. After washings, 20 L serum aliquots (ITC-spiked and unspiked of every serum sample) and 100 ng Eu-labeled 7B9 MAb in 20 L insulation layer II (ILII, Radiometer/Innotrac Diagnostics Oy) were added into triplicate wells. The wells were incubated for 1 h at 36°C, 900 rpm in a plate shaker (iEMS incubator/shaker, Thermo Electron/Labsystems, www.thermoscientific.com). The washed wells were then dried, and we measured the time-resolved fluorescence directly from the surface with a Victor ϫ4 Multilable Counter (Perkin-Elmer/Wallac, www. perkinelmer.com). Finally, we calculated sample specific recoveries for different capture epitopes by comparing the ITC-specific signal of each sample to the mean signal of cTnAAb-negative samples.
IMMUNOASSAYS FOR DETECTING HUMAN cTnAABs
Serum samples were diluted 5-fold with ILII, and the fluorescence signal was measured from each prediluted sample with and without ITC addition (30 g/L cTnI). 
SAMPLES
The study protocols were approved by the local ethics committees. Informed consent was obtained from all participants, and the study was conducted in accordance with the Declaration of Helsinki of 1975 as revised in 2006.
We performed epitope specificity studies with serum samples collected from apparently healthy volunteers (n ϭ 20) at the Department of Biotechnology, University of Turku, between 2010 and 2011. Ten of these samples were known to be cTnAAb negative and 10 cTnAAb positive according to the previously published cTnAAb assay (10, 21 ) . Briefly, cTnAAbs of the serum sample were first bound to ITC, and the formed ITC-cTnAAb complexes were subsequently captured on an SA-coated microtiter well preimmobilized with 150 ng biotinylated MAbs 4C2 and MF4. Finally, we detected captured cTnAAbs with 40 ng Eu-labeled 3D3 MAb. A sample was defined to be negative or positive as described above.
We analyzed total IgG and IgG subclasses in admission and 3-month follow-up serum samples from 28 chest pain patients from a substudy (10 ) of 81 non-ST-elevation ACS patients. Samples were collected between 1998 and 2000 from 9 different central hospitals in Finland for a placebo-controlled study on clarithromycin treatment of ACS patients, as described earlier (22 ) . The samples were stored at Ϫ70°C and had been thawed a few times before the cTnAAb measurements. We used the total IgG assay to categorize the patients into 2 study groups: the first group included 14 cTnAAb-negative patients, and the second group 14 cTnAAb-positive patients at 3-month follow-up.
STATISTICAL ANALYSIS
We analyzed differences in IgG-specific signals between sampling points with PASW Statistics 18 software (SPSS, www-01.ibm.com/software/analytics/ spss) using the Wilcoxon signed ranks test. All cTnAAb-negative samples were given a value of 50 counts (the lowest positive signal divided by 2). P values Ͻ0.05 were considered statistically significant.
Results
To evaluate the cTnAAb binding sites on the cTnI molecule, we measured ITC recovery with 19 different cTnI-specific capture antibodies using the same troponin C-specific antibody as a tracer. Although the mean ITC recovery in cTnAAb-positive samples for all 19 epitopes was 89%, mean recovery values for single cTnI epitopes ranged from 37% to 211% (Fig. 1A) . The lowest mean recoveries were obtained for epitopes on the midfragment and N-terminal parts of the C-terminus. In addition, we found considerable variation in the individual recoveries of cTnAAb-positive samples: the minimum and maximum recoveries for single epitopes ranged from 4% to 92% and 78% to 309%, respectively. The comparison between the sitespecific recoveries of 3 cTnAAb-positive subjects in Fig. 1B demonstrates that interindividual variation in interference differs between epitopes.
To study the IgG subclasses of cTnAAbs, we analyzed the cTnAAbs with total IgG and 4 subclassspecific assays. All 14 chest pain patients chosen for the cTnAAb-negative group were cTnAAb negative by the total IgG assay at both sampling points. In the 14 patients chosen for the cTnAAb-positive group, 6 were positive at admission and 8 reached positivity at follow-up. The specific signals of these IgG-positive samples ranged from 105 to 69 502 counts (median 2 111 counts). As illustrated in Table 2 , none of the samples in the cTnAAb-negative group were IgG1 or IgG2 positive, but 4 admission and 5 follow-up samples were weakly positive for IgG3 and/or IgG4 (specific signal 125-794 counts, median 242). Although all IgG subclasses 1-4 were observed in the cTnAAb-positive group (specific signal 101-115 579 counts, median 620), IgG4 had the highest prevalence and was detected in 8 admission and 11 follow-up samples. In addition, 3 admission and 10 follow-up samples from the cTnAAb-positive group were positive simultaneously for 2-4 subclasses (Table 3 ). According to all 5 IgG assays studied, the specific signals were generally higher at follow-up compared to the admission levels, indicating higher cTnAAb titers and/or improved binding affinity (Fig. 2) . Differences between sampling points were statistically significant (P Ͻ 0.05), with all assays except the IgG3-specific assay (P ϭ 0.249).
Discussion
Currently the reasons and mechanisms for initiation and maintenance of cTnAAbs are unclear, and their possible clinical and diagnostic significance remains open. Although cTnAAbs have been established as an important analytical confounder in cTnI assays, detailed data on their molecular characteristics are scarce. Therefore, the aim of this study was to characterize the epitope specificity and IgG subclass distribution of these autoantibodies. Our epitope specificity studies confirm the previously published observation (23 ) that the stable midfragment of the cTnI molecule is frequently targeted by cTnAAbs but also demonstrate that the cTnAAb interference extends beyond the midfragment, in particular toward the C-terminus. Although some epitopes may be less prone to cTnAAb-related interferences, our ITC recovery data for 10 cTnAAb-positive samples show that none of the studied epitopes completely escaped it. In addition, since the area of strongest interference varied between different individuals, the use of 3 or more carefully selected binding sites should be considered in future cTnI assays.
Besides being able to block the binding of assay antibodies, the observed recoveries clearly Ͼ100% imply that cTnAAbs may also stabilize some epitopes or enhance the affinity of assay antibodies against their binding sites. Nevertheless, our results from this study confirm our recently published conclusion that novel cTnI assays based on antibody configurations different from those derived by the IFCC-recommended midfragment approach improve cTnI detection in cTnAAb-positive samples and also prove our preliminary assumption that the cTnI-specific interference is even more heterogeneous than initially reported (4 ) .
Eight chest pain patients of the cTnAAb-positive group became positive between sampling points. Additionally, specific signals with all 5 cTnAAb assays were generally higher 3 months after the index event. These data confirm that cardiac troponin leakage from cardiomyocytes during a primary ischemic injury may induce an autoimmune response leading to cTnAAb formation (6, 10 ) . Alternatively, the leakage may serve as a booster of a previous immunization, which can both increase cTnAAb titers in blood and improve the affinity of formed autoantibodies.
In the cTnAAb-positive group, all IgG subclasses were detected and 46% of individual sera were positive for multiple subclasses. Because the frequency of cTnAAb-positive samples observed with certain subclass-specific assays is related to assay sensitivity, direct comparison between these frequencies is not possible. However, it is noteworthy that IgG4, which is generally the least frequent of the 4 IgG subclasses, was the most commonly detected cTnAAb in this study (found in 68% of samples in the cTnAAb-positive group). Because repeated antigenic stimulation is known to promote IgG4-type antibody formation, the appearance of IgG4-type cTnAAbs suggests that longer-term cardiac troponin leakage may have occurred in cardiac patients before the acute event. Also interesting is that IgG4 is frequently considered to be a benign and nonpathogenic antibody with even positive effects in some allergic reactions (24 ) . Both of these points may be linked to the observation that as a result of the half-antibody exchange reaction (Fab-arm exchange), most IgG4-type antibodies are bispecific antibodies with two different antigen-binding sites that make the molecules functionally monovalent for a given antigen (25 ) . Thus the high prevalence of IgG4-type cTnAAbs may also explain why our attempts to develop bridge-type immunoassays that use the same antigen as a capture and a tracer for cTnAAb detection have not succeeded (results not shown). Another feature of IgG4-type antibodies is that they may have a high affinity for various animal IgGs, such as mouse IgG, via their constant regions rather than their antigen-binding sites (26, 27 ) . If cardiac troponin-specific IgG4s bind to animal IgGs used as immunoassay reagents, then in addition to blocking specific cardiac troponin epitopes, they could potentially interfere with cardiac troponin immunoassays nonspecifically.
This study was limited in investigating only the IgG-type antibodies; although IgM-type antibodies are predominant in a primary immune response, IgM response was not studied. The discrepancy between total IgG and subclass-specific assay results illustrates the challenges in autoantibody assays. First, different affinities of tracer antibodies lead to varying assay sensitivity, which cannot be determined due to the lack of defined standards. Second, as demonstrated with our epitope specificity studies, cTnAAbs form a heterogeneous population in which precise epitope specificity and binding affinity against cardiac troponin may vary widely. In addition, the use of different assay formats makes direct comparison between different reports impossible. Although many published cTnAAb assays use directly coated cTnI or cTnT surfaces, an advantage in our assays is that we correct the results for the nonspecific binding of other antibodies by measuring the sample-specific backgrounds, which seem to fluctuate substantially between individuals (21 ). On the other hand, because we have used ITC as a target molecule in our cTnAAb assays, we cannot differentiate cTnI-and cTnT-specific autoantibody positivity.
In conclusion, because cTnAAbs are common even in apparently healthy individuals and the cTnAAb formation may be triggered or boosted in acute cardiac events, their analytical interference effects should be acknowledged in the design of future cTnI assays. The midfragment of the cTnI molecule is usually the only detection site of commercial cTnI assays but is also the site most frequently targeted by cTnAAbs. In addition, our detailed epitope screening clearly demonstrates that the whole cTnI molecule can suffer from cTnAAbrelated interferences and that there is remarkable individual variation in the affected sites and in the extent of interference. Therefore, the use of 3 or more carefully selected epitopes should be considered to circumvent the negative interference of the highly heterogeneous cTnAAbs.
